Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
65.42 ^USD	+0.23%		-2.01%	-19.24%

Apr. 26	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	MT
Apr. 26	Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV	Apr. 26	BU
Gilead: Q1 Earnings Snapshot	Apr. 25	AQ
Gilead Sciences Announces First Quarter 2024 Financial Results	Apr. 25	BU
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024	Apr. 08	BU
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six	Mar. 28	BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	Mar. 28	BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	Mar. 28	AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay	Mar. 25	AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay	Mar. 22	BU
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant	Mar. 18	BU
Gilead Sciences : Kite Cell Therapy Analyst & Investor Event	Mar. 14	PU
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer	Mar. 11	BU
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities	Mar. 06	BU
Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health	Mar. 06	AQ
Gilead Sciences, Inc. - New Real-World Data Further Support the Use of Veklury for People Hospitalized With COVID-19	Mar. 06	AQ
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers	Mar. 06	BU
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19	Mar. 05	BU
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health	Mar. 05	BU
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.	Feb. 27	BU
U.S. FDA Approves Expanded Indication for Gilead's Biktarvy to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance	Feb. 27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Press Releases

Filters